Johnson & Johnson Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31)
Johnson & Johnson (JNJ) had Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) of $1.00 million as of 2012-01-01, per its 10-K filed 2013-02-22.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain · last filed 2013-02-22
- 2012-01-01: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $1.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) |
|---|---|
| 2012-01-01 | $1.00M 10-K · filed 2013-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |